Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Almogran, Axert, Ralpax
Almeta (almotriptan malate) is a selective serotonin receptor agonist, specifically targeting the 5-HT1B and 5-HT1D receptors, primarily used to treat acute migraine attacks with or without aura. It belongs to the triptan class of drugs, which are known for their vasoconstrictive properties in cranial blood vessels, believed to be a key mechanism in relieving migraine pain. Almotriptan is not intended for preventative use or for treating other headache types like cluster headaches or hemiplegic migraines.
For the acute treatment of migraine attacks with or without aura.
Almeta may increase the risk of serious cardiovascular events, such as myocardial infarction or stroke, in patients with pre-existing cardiovascular disease or risk factors. It should not be used in patients with hemiplegic or basilar migraine.
Outcome:
Additive vasoconstriction, potentially leading to hypertension or other cardiovascular complications.
Mechanism:
Both drugs constrict blood vessels.
Outcome:
Increased almotriptan levels.
Mechanism:
Propranolol may inhibit almotriptan metabolism.
Outcome:
May enhance the analgesic effect of almotriptan.
Mechanism:
Caffeine has its own analgesic properties.
Most likely new formulation: Fast-dissolving oral film (Year: 2026, 70% confidence)
Based on current usage trends and clinical trial data, there is a low ( <5%) likelihood of any major regulatory changes for Almeta in the next 2 years.
Triptan, Serotonin Receptor Agonist, Antimigraine Agent
Sulfonamide